<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00452478</url>
  </required_header>
  <id_info>
    <org_study_id>SPD405-403</org_study_id>
    <secondary_id>2006-003364-64</secondary_id>
    <nct_id>NCT00452478</nct_id>
  </id_info>
  <brief_title>Conversion From Standard Phosphate Binder Therapy to Fosrenol® (Lanthanum Carbonate) in Chronic Kidney Disease Stage 5</brief_title>
  <official_title>A Phase IV, Open-Label, Multi-Centre Trial Evaluating the Conversion From Standard Phosphate Binder Therapy to Fosrenol® in Chronic Kidney Disease Stage 5 Patients on Haemodialysis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shire</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shire</source>
  <brief_summary>
    <textblock>
      The main aim of this research study is to see if giving Fosrenol®, a chewable tablet, to
      patients on haemodialysis works as well as other treatments currently used to lower blood
      phosphorus levels.
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    This study was stopped by the sponsor based on a non-safety related corporate decision
  </why_stopped>
  <start_date>May 2007</start_date>
  <completion_date type="Actual">December 2007</completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of subjects achieving serum phosphorus levels of less than or equal to 1.78 mmol/L (5.5 mg/dL) following treatment with Fosrenol at Week 12 compared to treatment with their previous phosphate binder therapy</measure>
    <time_frame>12 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>The maintenance of mean serum phosphorus levels following treatment with 2250 mg/day of Fosrenol</measure>
    <time_frame>at Week 2 compared to baseline</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Biochemical and haematological parameters</measure>
    <time_frame>measured throughout the study</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assess safety &amp; tolerability</measure>
    <time_frame>Throughout the study</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">68</enrollment>
  <condition>Kidney Diseases</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lanthanum carbonate</intervention_name>
    <description>2250mg/day starting dose of lanthanum carbonate administered orally, in divided doses, with meals (500mg 750mg and 1000mg strengths)for 2 weeks; dose titration will occur based on serum phosphorus results not to exceed 3000mg/day.</description>
    <arm_group_label>1</arm_group_label>
    <other_name>FOSRENOL</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female subjects greater than or equal to 18 years of age receiving a stable
             regimen of haemodialysis for chronic kidney disease (CKD) Stage 5 (defined as
             haemodialysis two or three times per week for at least two months prior to screening).

          -  Females of child bearing potential (FOCP) must be non-pregnant, non-lactating, have a
             negative serum beta human chorionic gonadotropin (HCG) test, and agree to comply with
             any applicable contraceptive requirements of the protocol.

          -  Subjects on a stable phosphate binder dose (defined as no change in medication or
             dosage for at least the one month prior to screening) with a serum phosphorus level
             between greater than 1.78 and less than or equal to 2.43 mmol/L (5.5 and 7.5 mg/dL).

        Exclusion Criteria:

          -  Subjects with a corrected serum calcium level less than 2.1 mmol/L (8.5 mg/dL).

          -  Subjects with an intact parathyroid hormone (iPTH) level greater than 500 pg/mL, or a
             history of previous parathyroidectomy within 12 months of screening.

          -  Subjects with any significant bowel obstruction, active inflammatory bowel disease,
             gastrointestinal (GI) motility disorders, abnormal or irregular bowel motion, or a
             history of major GI surgery within the last 6 months will be excluded.

          -  Subjects receiving aluminium, magnesium, or combination therapy other than sevelamer
             hydrogen chloride (HCl) and calcium as a phosphate binder at the time of screening
             will be excluded.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mario Cozzolino, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Renal Physician</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Landeskrankenhaus Feldkirch, Abteilung fur Nephrologie und dialyse</name>
      <address>
        <city>Feldkirch Tisis</city>
        <zip>A-6807</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Krankenhaus Elisabethinen/Dialysestation</name>
      <address>
        <city>Linz</city>
        <zip>A-4010</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ziekenhuis Zuid Oost Limburg</name>
      <address>
        <city>Genk</city>
        <zip>3600</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Frederica Sygehus</name>
      <address>
        <city>Fredericia</city>
        <zip>7000</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Holbaek Sykehus</name>
      <address>
        <city>Holbaek</city>
        <zip>DK-4300</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sygehus Viborg</name>
      <address>
        <city>Viborg</city>
        <zip>88 00</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dialysezentrum Barmbek</name>
      <address>
        <city>Hamburg</city>
        <zip>22297</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dialysezentrum Heilbronn</name>
      <address>
        <city>Heilbronn</city>
        <zip>74076</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dialyse Leipzig</name>
      <address>
        <city>Leipzig</city>
        <zip>04178</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nephrologisches Zentrum Emsland</name>
      <address>
        <city>Lingen</city>
        <zip>49808</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>nephrologische Schwerpunktpraxis</name>
      <address>
        <city>Oldenburg</city>
        <zip>26127</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>diabetologische Schwerpunktpraxis</name>
      <address>
        <city>Villingen-Schwenningen</city>
        <zip>78054</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Milan, San Paolo Hospital, Renal Division</name>
      <address>
        <city>Milan</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gelre Ziekenhuizen</name>
      <address>
        <city>Apeldoorn</city>
        <zip>7334 DZ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Austria</country>
    <country>Belgium</country>
    <country>Denmark</country>
    <country>Germany</country>
    <country>Italy</country>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>December 2007</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 23, 2007</study_first_submitted>
  <study_first_submitted_qc>March 26, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 27, 2007</study_first_posted>
  <last_update_submitted>June 6, 2014</last_update_submitted>
  <last_update_submitted_qc>June 6, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 9, 2014</last_update_posted>
  <responsible_party>
    <name_title>Timothy Whitaker, M.D.</name_title>
    <organization>Shire Pharmaceutical</organization>
  </responsible_party>
  <keyword>Hyperphosphataemia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Renal Insufficiency, Chronic</mesh_term>
    <mesh_term>Kidney Failure, Chronic</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

